Internal Reference Number: FOI_8911
Date Request Received: 17/09/2025 00:00:00
Date Request Replied To: 29/09/2025 00:00:00
This response was sent via: By Email
Request Summary: Biologics Dermatology
Request Category: Researcher
| Question Number 1: I would like to raise an FOI request, which I hope you will be able to help me with. How many new patients were treated for Psoriasis by the Trust's Dermatology Department in the latest 3-month period of June, July and August (or the latest 3 months available) with the treatments I have provided below? Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments before the 1st of June 2025, they can be classed as a new patient for the purposes of this question. 鈥� Adalimumab [Humira] 鈥� Adalimumab [All Biosimilars] 鈥� Etanercept [Enbrel] 鈥� Etanercept [All Biosimilars] 鈥� Infliximab [Remicade] 鈥� Infliximab [All Biosimilars] 鈥� Ustekinumab [Stelara] 鈥� Ustekinumab [All Biosimilars] 鈥� Apremilast [Otezla] 鈥� Bimekizumab [Bimzelx] 鈥� Brodalumab [Kyntheum] 鈥� Certolizumab [Cimzia] 鈥� Deucravacitinib [Sotyktu] 鈥� Dimethyl Fumarate [Skilarence] 鈥� Guselkumab [Tremfya] 鈥� Ixekizumab [Taltz] 鈥� Risankizumab [Skyrizi] 鈥� Secukinumab [Cosentyx] 鈥� Spesolimab [Spevigo] 鈥� Tildrakizumab [illumetri] | |
| Answer To Question 1: Please see our response to this FOI in the spreadsheet attached. To accompany this answer to question 1 please also see the documents listed below:  13256 - FOI_8911 - Biologics Dermatology - FOR ISSUE.xlsx | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at SA国际传媒 Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
